Recce Pharmaceuticals Ltd. · ASX:RCE
Recce Pharmaceuticals — Investor Presentation (February 2023)
27 slides from Recce Pharmaceuticals's investor presentation, February 2023

Slide 1: Corporate Presentation
Corporate Presentation February 2023 ASX:RCE FSE:R9Q

Slide 2: Disclaimer
Disclaimer DISCLAIMER This presentation has been prepared by Recce Pharmaceuticals Ltd (the “Company”). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this pre

Slide 3: Board Structure
Board Structure Dr John Prendergast James Graham Michele Dilizia Justin Ward Executive Chairman Chief Executive Officer Chief Scientific Officer Executive Director & (Shares: 250,000) (Shares: 6,031,932 – 3.39%) (Shares: 3,543,485 – 2.0%) Principal Quality Chemist (Options: 2,175,000) (Options: 2,25

Slide 4: A Versatile Technology Platform
A Versatile Technology Platform R529 • Biotech company developing Anti-infectives targeting both bacterial and viral indications • Strong IP and own manufacturing capability • Qualified Infectious Disease Product designation • 10 years market exclusivity plus fast track approval* • Versatile deliver

Slide 5: Strong Pipeline
Strong Pipeline Over Various Indications and Upcoming Inflection Points Asset and Indications Discovery Pre-Clinical Phase I Phase II Phase III Market Route of Administration Serious/life threatening bacterial R327 Intravenous* infections including sepsis Urinary tract infections including urosepsis

Slide 6: Sepsis – it’s a big problem!
Sepsis – it’s a big problem! 2 What is Sepsis? Economic Impact Social Impact Sepsis is a life-threatening Is the most expensive Kills more people in the US inflammatory response to condition to treat in the than prostate, breast cancer infection that has spread in last 8 years5. and HIV/AIDS combine

Slide 7: Sepsis Patient Journey
Sepsis Patient Journey Patient Presents at the Hospital Early treatment with the correct antibiotic is key to improving patient outcome • 1/3 of patients present non-specific symptoms, leading to delayed treatment and high mortality rate. • Mortality from sepsis increases by as much as 8% for every

Slide 8: The Need for a New Class of Antibiotics: Synthetic Anti-Infectives
The Need for a New Class of Antibiotics: Synthetic Anti-Infectives • NO pre-formed natural superbugs. • Entirely man-made and designed with purpose. • Universal Mechanism of Action - does not succumb to resistance. • Broad Spectrum capability and maintains its activity even with repeated use. • Empo

Slide 9: Independent Study Undertaken on R327 MoA
Independent Study Undertaken on R327 MoA1 By Leading Experts in Bacterial MoA Analysis Stage 1 Stage 2 R327 permeabilizes cell membrane and enters the cell R327 interrupts bacterial cellular energetics via ATP Synthesis Stage 3 Stage 4 Cellular division & non-dividing cell functions are disrupted R3

Slide 10: RECCE 327 Multi-Layered Mechanism of Action
RECCE® 327 Multi-Layered Mechanism of Action1 R327 rapidly & irreversibly R327 affects the assembly of R327 results in the shuts down cellular energetics bacterial cell division complex, decreased formation of the (adenosine triphosphate (ATP) components that require cellular bacterial cell division

Slide 11: RECCE Activity Against Escherichia coli
RECCE® 327 Activity Against Escherichia coli • E. coli grows fast. Eukaryotic cells healthy Without R327 R327 (3,000 ppm) and not affected. • R327 at 3,000 ppm shown to be highly effective against E. coli without affecting growing, healthy eukaryotic cells. • R327 rapidly and irreversibly shuts down

Slide 12: RECCE Activity Against Staphylococcus aureus
RECCE® 327 Activity Against Staphylococcus aureus • S. aureus bacterial growth slower than E. coli, not Without R327 R327 (2,300 ppm) affecting eukaryotic cells. • R327 at 2,300 ppm shown to be highly effective against S. aureus without affecting growing, healthy eukaryotic cells. • R327 rapidly and

Slide 13: Pre-Clinical Study Outlook
Pre-Clinical Study Outlook • Recce’s new Anti-Infective Research (AIR) Unit: Fit-for-purpose laboratory space – Located within Murdoch Children’s Research Institute Dr Philip Sutton’s Pre-Clinical Update – Recce will streamline ongoing pre-clinical programs and explore new research development oppor

Slide 14: Phase I Human Clinical Trial Complete
Phase I Human Clinical Trial Complete 120x dose amount* 6,000 mg ✓ • Study to assess IV infusion of RECCE® 327 in healthy male subjects as a single High Dose 80x dose amount* 4,000 mg ✓ 7-10 subjects in each ascending dose. cohort: 2 control, 8 R327 40x dose amount* 2,000 mg ✓ • Randomized, double-b

Slide 15: Phase I Human Clinical Trial – High Dose 6,000 mg
Phase I Human Clinical Trial – ‘High Dose’ 120x dose amount* 80x Why 6,000mg (R327) over 1 hour infusion? dose amount* 6,000 mg ✓ 40x dose amount* 4,000 mg ✓ • Study objectives achieved – Phase II preparations are underway 2,000 mg ✓ • R327 dosing broadly in efficacy range based on animal models – P

Slide 16: R327 faster acting than existing antibiotics
R327 faster acting than existing antibiotics – no prolonged exposure needed E.coli Xen14 Biofilm 180000 • R327 kills pathogenic bacteria at a 150000 50% faster rate. 50%PEG PEG 120000 B0076 Untreated • R327 designed to work faster than all Luminescence* CEPH Cephalexin existing antibiotics, reinforc

Slide 17: Reason for Optimism in Treating UTI/Sepsis
Reason for Optimism in Treating UTI/Sepsis Dr Alan Dunton’s Clinical Update Concentration of R327 in Ratio Urine Compared to Urine/Plasma - Plasma 15x 13x 15x 17x In over 60 healthy 14x subjects 20x 13x – R327 primary route of elimination appears to be – Opportunities for therapeutic in array of UTI

Slide 18: RECCE Kills Quickly in the Urine
RECCE® 327 Kills Quickly in the Urine E. coli ATCC 25922 Viable Cells Treated with RECCE® 327 in Urine + 10%LB 10.00 • R327 in the presence of human urine was able to 9.00 have a fast (near minutes effect against E. coli and irreversible 8.00 • Bacteria could not be ‘washed out’ and regrown 7.00 • R

Slide 19: Background on UTIs
Background on UTIs • Urinary tract infection (UTI) is one of the most common infectious diseases • The most common pathogen causing UTIs is Escherichia coli (E. coli) with 62% One in three uncomplicated UTIs in young healthy ‒ The resistance among the isolates of E. coli are: ampicillin (86%), women

Slide 20: Topical RECCE – Phase I/II
Topical RECCE® 327 – Phase I/II Patient examples from ongoing Burn Wound trial • Patients suffered major burn injury. • Multiple bacterial species in and surrounding wound. • Growth swabs with organisms including pathogens from the ESKAPE group of bacteria. • Post R327 treatment: healthy skin growth

Slide 21: Phase I/II Diabetic Foot Ulcer (DFU) Clinical Trial
Phase I/II Diabetic Foot Ulcer (DFU) Clinical Trial Clinical Trial Overview Market Opportunity • Human Research Ethics approval received • The total medical cost for treating diabetic • Phase I/II to assess safety and efficacy of R327 foot diseases in the United States is on mild skin and soft tissu

Slide 22: Patents
Patents Four families across all major markets Patent Patent Patent Expiry Expiry Expiry Filed Family 1 Family 2 Family 3 Australia ✓ 2028 ✓ 2037 Accepted 2037 USA ✓ 2029 ✓ 2037 ✓ 2037 Europe ✓ 2028 ✓ 2037 ✓ 2037 Germany ✓ 2028 ✓ 2037 ✓ 2037 Spain ✓ 2028 ✓ 2037 ✓ 2037 France ✓ 2029 ✓ 2037 ✓ 2037 UK

Slide 23: In-house Manufacturing Capabilities
In-house Manufacturing Capabilities Manufacturing facility in Sydney’s Macquarie Park • Raw materials plentiful and cheap – few $/Kg • No expensive waste – 99.9% product yield • Automated manufacture process taking approx. 1 hour • 500 doses per fully automated run • Quality and Quantity demonstrate

Slide 24: Recce Pharmaceuticals Ltd – Capital Structure
Recce Pharmaceuticals Ltd – Capital Structure 7% Snapshot Tickers ASX:RCE, FSE:R9Q Market Cap (approx.) AUD $102 million 28% Priced at AUD $0.572/share Top 20 Cash and deposits* AUD $8.05 million** Shareholder Distribution 30 January 2023 Outstanding shares 178.18 million Average daily volume 57.6k

Slide 25: Upcoming Clinical Milestones
Upcoming Clinical Milestones • In-vivo pre-clinical Michele Dilizia Scientific Strategy Update ‒ Pre-Sepsis UTI Models in Rats ✓ • Phase I clinical trials ‒ R327 I.V. Single Dose, Safety/Tolerability/PK study in healthy subjects ✓ • Phase II UTI clinical trial (Pre-Sepsis) ‒ Single (as now completed

Slide 26: Summary
Summary Proprietary new class of anti-infectives against bacteria and viruses, protected by Composition of Matter Patent. Fast development plans initially targeting: Sepsis, UTI, Burn wounds, Diabetic Foot Ulcers, COVID-19 and a suite of pre-clinical indications. Strong pre-clinical data package dem

Slide 27: Thank you
Thank you James Graham Managing Director and Chief Executive Officer Recce Pharmaceuticals Ltd ASX:RCE; FSE:R9Q +61 2 9256 2572 james.graham@recce.com.au recce.com.au
Source: Internet Archive copy of recce.com.au
More decks from Recce Pharmaceuticals Ltd.
Shareholder Meeting (November 2026)19 slides · Nov 6, 2026
Investor Presentation (November 2026)45 slides · November 2026
Investor Presentation (October 2026)42 slides · October 2026
Shareholder Meeting (September 2026)10 slides · Sep 2, 2026
Investor Presentation (September 2026)42 slides · September 2026
Investor Presentation (August 2026)40 slides · August 2026